Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 06 – Jul 13, 2026
Concurrent Chemoradiotherapy Plus Immunotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer: A Randomized, Single-Center, Phase II Trial of Early Tumor Regression and Pro-Inflammatory Tumor Microenvironment Remodeling.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This randomized, single-center, Phase II trial investigated the addition of immunotherapy to concurrent chemoradiotherapy (CICRT) in 18 patients with high-risk Stage III-IVA locally advanced cervical cancer (LACC) to assess early tumor regression and immune modulation. CICRT showed a numerical advantage in reducing tumor volume compared to CCRT alone (mean residual tumor volume: 3.0% vs. 7.4%, p = 0.080, 95% CI: -9.3%-0.6%, Cohen’s d = 0.180), though these findings were not statistically significant. Single-cell RNA sequencing of paired biopsies (n = 12) demonstrated pro-inflammatory remodeling of the tumor microenvironment, including upregulation of MHC-II genes and reduced regulatory T cells. The results suggest the potential of CICRT for overcoming TME suppression in LACC, although further research is warranted to confirm efficacy and statistical significance.
10.1002/mco2.70856
Jun 08 – Jun 15, 2026
Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.
FRONT IMMUNOL · Q1 JOURNAL - RANK #32/183
This exploratory translational study of the PRIMMO clinical trial (NCT03192059) prospectively analyzed blood-based immune profiles from 19 advanced cervical cancer (CC) and 24 endometrial cancer (EC) patients treated with an ICB-based regimen combining PD-1 blockade, radiotherapy, and immune modulation. Peripheral blood was collected at baseline, on-treatment (week 7), and post-treatment (week 26 or earlier) and assessed via multicolor flow cytometry and ELISA. Key findings include that CTLA-4+PD-1+CD4+ T cells and CD161+CD56+CD16+ NK cells at baseline were associated with survival, while responders showed stable immune profiles and non-responders exhibited sustained decreases in pDCs, increases in activation markers (CD69, CD137, HLA-DR) on T cells and NK cells, expansion of MDSCs and Tregs, elevated kynurenine/tryptophan ratio, and increased sPD-1 levels. The authors conclude that non-response is characterized by systemic immune imbalance rather than inactivity, supporting longitudinal immune monitoring in future trials.
10.3389/fimmu.2026.1794131
May 25 – Jun 01, 2026
Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.
J GYNECOL ONCOL · Q1 JOURNAL - RANK #14/140
This multicenter prospective cohort study evaluated the efficacy and safety of extended-field intensity-modulated radiotherapy (EF-IMRT) combined with concurrent chemotherapy and high-dose-rate (HDR) brachytherapy in 204 patients with locally advanced cervical cancer and positive para-aortic (PALN) or common iliac lymph nodes (CILN). The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and adverse events. The 3-year and 5-year PFS rates were 68.3% and 64.6%, respectively, while OS rates were 76.4% and 69.5%, and 5-year LPFS and DMFS were 83.1% and 70.1%. The study concluded that EF-IMRT with concurrent chemotherapy was tolerable and effective, with favorable local control and OS outcomes.
10.3802/jgo.2026.37.e114